Veracyte, Inc.
Feb 2, 2017

Veracyte to Present at LEERINK Partners 6th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 2, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, chairman of the board, president and chief executive officer, will present at the LEERINK Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 1:00 p.m. ET in New York, NY.

The live audio webcast from the LEERINK conference and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. The webcast will be available shortly after conclusion of the presentation and archived on the company's website for 90 days following the presentation.

About Veracyte
Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Veracyte and the Veracyte logo are trademarks of Veracyte, Inc.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/veracyte-to-present-at-leerink-partners-6th-annual-global-healthcare-conference-300400835.html

SOURCE Veracyte

News Provided by Acquire Media